• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2021 年 12 月至 2022 年 6 月期间对 SARS-CoV-2 奥密克戎变异病毒感染的抗体反应。

Antibody Response to Symptomatic Infection With SARS-CoV-2 Omicron Variant Viruses, December 2021-June 2022.

机构信息

Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee, USA.

出版信息

Influenza Other Respir Viruses. 2024 Jul;18(7):e13339. doi: 10.1111/irv.13339.

DOI:10.1111/irv.13339
PMID:39012045
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11250392/
Abstract

We describe humoral immune responses in 105 ambulatory patients with laboratory-confirmed SARS-CoV-2 Omicron variant infection. In dried blood spot (DBS) collected within 5 days of illness onset and during convalescence, we measured binding antibody (bAb) against ancestral spike protein receptor binding domain (RBD) and nucleocapsid (N) protein using a commercial multiplex bead assay. Geometric mean bAb concentrations against RBD increased by a factor of 2.5 from 1258 to 3189 units/mL and by a factor of 47 against N protein from 5.5 to 259 units/mL between acute illness and convalescence; lower concentrations were associated with greater geometric mean ratios. Paired DBS specimens may be used to evaluate humoral response to SARS-CoV-2 infection.

摘要

我们描述了 105 例经实验室确诊的 SARS-CoV-2 奥密克戎变异株感染的门诊患者的体液免疫反应。在发病后 5 天内和恢复期采集的干血斑 (DBS) 中,我们使用商业多重珠粒分析测定了针对原始刺突蛋白受体结合域 (RBD) 和核衣壳 (N) 蛋白的结合抗体 (bAb)。与急性疾病相比,恢复期 RBD 的 bAb 浓度从 1258 单位/毫升增加到 3189 单位/毫升,增加了 2.5 倍;针对 N 蛋白的 bAb 浓度从 5.5 单位/毫升增加到 259 单位/毫升,增加了 47 倍;较低的浓度与更高的几何平均比值相关。配对的 DBS 标本可用于评估针对 SARS-CoV-2 感染的体液免疫反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b1/11250392/e4a53a275d82/IRV-18-e13339-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b1/11250392/e4a53a275d82/IRV-18-e13339-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b1/11250392/e4a53a275d82/IRV-18-e13339-g001.jpg

相似文献

1
Antibody Response to Symptomatic Infection With SARS-CoV-2 Omicron Variant Viruses, December 2021-June 2022.2021 年 12 月至 2022 年 6 月期间对 SARS-CoV-2 奥密克戎变异病毒感染的抗体反应。
Influenza Other Respir Viruses. 2024 Jul;18(7):e13339. doi: 10.1111/irv.13339.
2
Antibody response to symptomatic infection with SARS-CoV-2 Omicron variant viruses, December 2021-June 2022.2021年12月至2022年6月期间,对感染新冠病毒奥密克戎变异株出现症状后的抗体反应。
medRxiv. 2023 Nov 18:2023.11.17.23298700. doi: 10.1101/2023.11.17.23298700.
3
Anti-SARS-CoV-2 Antibody Levels Associated With COVID-19 Protection in Outpatients Tested for SARS-CoV-2, US Flu Vaccine Effectiveness Network, October 2021-June 2022.与 COVID-19 保护相关的抗 SARS-CoV-2 抗体水平,在 2021 年 10 月至 2022 年 6 月期间,美国流感疫苗有效性网络对检测 SARS-CoV-2 的门诊患者进行检测。
J Infect Dis. 2024 Jul 25;230(1):45-54. doi: 10.1093/infdis/jiae090.
4
SARS-CoV-2 Infection Severity Is Linked to Superior Humoral Immunity against the Spike.SARS-CoV-2 感染严重程度与针对刺突蛋白的体液免疫优势相关。
mBio. 2021 Jan 19;12(1):e02940-20. doi: 10.1128/mBio.02940-20.
5
Diversified humoral immunity and impacts of booster vaccines: SARS-CoV-2 antibody profile and Omicron BA.2 neutralization before and after first or second boosters.多元化的体液免疫和加强疫苗的影响:初次或第二次加强针前后 SARS-CoV-2 抗体特征和奥密克戎 BA.2 的中和作用。
Microbiol Spectr. 2024 Oct 3;12(10):e0060524. doi: 10.1128/spectrum.00605-24. Epub 2024 Aug 20.
6
MVA-based vaccine candidates expressing SARS-CoV-2 prefusion-stabilized spike proteins of the Wuhan, Beta or Omicron BA.1 variants protect transgenic K18-hACE2 mice against Omicron infection and elicit robust and broad specific humoral and cellular immune responses.基于 MVA 的疫苗候选物表达了武汉、β或奥密克戎 BA.1 变异株的 prefusion-稳定化 Spike 蛋白,可保护 K18-hACE2 转基因小鼠免受奥密克戎感染,并引发强烈和广泛的特异性体液和细胞免疫反应。
Front Immunol. 2024 Aug 29;15:1420304. doi: 10.3389/fimmu.2024.1420304. eCollection 2024.
7
Declining Levels of Neutralizing Antibodies Against SARS-CoV-2 in Convalescent COVID-19 Patients One Year Post Symptom Onset.康复一年后 COVID-19 患者对 SARS-CoV-2 的中和抗体水平下降。
Front Immunol. 2021 Jun 16;12:708523. doi: 10.3389/fimmu.2021.708523. eCollection 2021.
8
Anti-SARS-CoV-2 serology based on ancestral RBD antigens does not correlate with the presence of neutralizing antibodies against Omicron variants.基于原始受体结合域(RBD)抗原的抗严重急性呼吸综合征冠状病毒2(SARS-CoV-2)血清学与针对奥密克戎变异株的中和抗体的存在不相关。
Microbiol Spectr. 2025 Jan 7;13(1):e0156824. doi: 10.1128/spectrum.01568-24. Epub 2024 Nov 20.
9
Characterization of the SARS-CoV-2 antibody landscape in Norway in the late summer of 2022: high seroprevalence in all age groups with patterns of primary Omicron infection in children and hybrid immunity in adults.2022 年夏末挪威的 SARS-CoV-2 抗体特征:所有年龄段的血清阳性率都很高,儿童中主要为奥密克戎感染模式,成人中为混合免疫。
BMC Infect Dis. 2024 Aug 20;24(1):841. doi: 10.1186/s12879-024-09670-w.
10
Longitudinal analysis of SARS-CoV-2 IgG antibody durability in Puerto Rico.波多黎各SARS-CoV-2 IgG抗体持久性的纵向分析。
Sci Rep. 2024 Dec 28;14(1):30743. doi: 10.1038/s41598-024-80465-4.

本文引用的文献

1
Anti-SARS-CoV-2 Antibody Levels Associated With COVID-19 Protection in Outpatients Tested for SARS-CoV-2, US Flu Vaccine Effectiveness Network, October 2021-June 2022.与 COVID-19 保护相关的抗 SARS-CoV-2 抗体水平,在 2021 年 10 月至 2022 年 6 月期间,美国流感疫苗有效性网络对检测 SARS-CoV-2 的门诊患者进行检测。
J Infect Dis. 2024 Jul 25;230(1):45-54. doi: 10.1093/infdis/jiae090.
2
Differential Severe Acute Respiratory Syndrome Coronavirus 2-Specific Humoral Response in Inactivated Virus-Vaccinated, Convalescent, and Breakthrough-Infected Subjects.灭活病毒疫苗接种、康复和突破性感染受试者中 SARS-CoV-2 特异性体液反应的差异。
J Infect Dis. 2023 Oct 3;228(7):857-867. doi: 10.1093/infdis/jiad320.
3
Prior SARS-CoV-2 infection and COVID-19 vaccine effectiveness against outpatient illness during widespread circulation of SARS-CoV-2 Omicron variant, US Flu VE network.
在 SARS-CoV-2 奥密克戎变异株广泛传播期间,既往 SARS-CoV-2 感染和 COVID-19 疫苗对门诊疾病的有效性,美国流感疫苗效果监测网络。
Influenza Other Respir Viruses. 2023 May;17(5):e13143. doi: 10.1111/irv.13143.
4
Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial.比较 COVE mRNA-1273 疫苗疗效试验中针对 COVID-19 的抗体检测作为保护相关性。
Sci Transl Med. 2023 Apr 19;15(692):eade9078. doi: 10.1126/scitranslmed.ade9078.
5
Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine.AZD1222(ChAdOx1 nCoV-19)疫苗3期试验的免疫相关分析。
NPJ Vaccines. 2023 Mar 11;8(1):36. doi: 10.1038/s41541-023-00630-0.
6
Kinetics of the Antibody Response to Symptomatic SARS-CoV-2 Infection in Vaccinated and Unvaccinated Individuals in the Blinded Phase of the mRNA-1273 COVID-19 Vaccine Efficacy Trial.mRNA-1273新冠疫苗有效性试验盲法阶段中接种和未接种个体对有症状的SARS-CoV-2感染的抗体反应动力学
Open Forum Infect Dis. 2023 Feb 13;10(3):ofad069. doi: 10.1093/ofid/ofad069. eCollection 2023 Mar.
7
Immunity of Heterologously and Homologously Boosted or Convalescent Individuals Against Omicron BA.1, BA.2, and BA.4/5 Variants.异源和同源加强或康复个体对奥密克戎 BA.1、BA.2 和 BA.4/5 变异株的免疫。
J Infect Dis. 2023 Jul 14;228(2):160-168. doi: 10.1093/infdis/jiad057.
8
Predicting the efficacy of variant-modified COVID-19 vaccine boosters.预测变异株改良 COVID-19 疫苗加强针的效力。
Nat Med. 2023 Mar;29(3):574-578. doi: 10.1038/s41591-023-02228-4. Epub 2023 Mar 2.
9
Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial.预防 19 型 COVID-19 疫苗疗效临床试验的免疫相关性分析。
Nat Commun. 2023 Jan 19;14(1):331. doi: 10.1038/s41467-022-35768-3.
10
Dried blood spots are a valid alternative to venipuncture for COVID-19 antibody testing.干血斑是一种替代静脉采血的有效方法,可用于 COVID-19 抗体检测。
J Immunol Methods. 2023 Feb;513:113420. doi: 10.1016/j.jim.2022.113420. Epub 2022 Dec 31.